Litcius/Paper detail

Design, synthesis, docking, ADMET studies, and anticancer evaluation of new 3-methylquinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers

Mohammed M. Alanazi, Ibrahim H. Eissa, Nawaf A. Alsaif, Ahmad J. Obaidullah, Wael A. Alanazi, Abdullah F. Alasmari, Hussam Albassam, Hazem Elkady, Alaa Elwan

2021Journal of Enzyme Inhibition and Medicinal Chemistry92 citationsDOIOpen Access PDF

Abstract

on the level of caspase-3, caspase-9, and BAX/Bcl-2 ratio was determined. Molecular docking studies were implemented to interpret the binding mode of the target compounds with the VEGFR-2 pocket. Furthermore, toxicity and ADMET calculations were performed for the synthesised compounds to study their pharmacokinetic profiles.

Topics & Concepts

SorafenibCytotoxicityChemistryIC50Docking (animal)ApoptosisCytotoxic T cellPharmacologyIn vitroLead compoundStereochemistryGrowth inhibitionBiochemistryCancer researchBiologyMedicineHepatocellular carcinomaNursingSynthesis and biological activitySynthesis and Biological EvaluationBioactive Compounds and Antitumor Agents
Design, synthesis, docking, ADMET studies, and anticancer evaluation of new 3-methylquinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers | Litcius